MX381440B - Composicion farmaceutica para tratar colitis ulcerativa. - Google Patents

Composicion farmaceutica para tratar colitis ulcerativa.

Info

Publication number
MX381440B
MX381440B MX2017003780A MX2017003780A MX381440B MX 381440 B MX381440 B MX 381440B MX 2017003780 A MX2017003780 A MX 2017003780A MX 2017003780 A MX2017003780 A MX 2017003780A MX 381440 B MX381440 B MX 381440B
Authority
MX
Mexico
Prior art keywords
ulcerative colitis
pharmaceutical composition
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2017003780A
Other languages
English (en)
Other versions
MX2017003780A (es
Inventor
Shunsuke Kageyama
Toshihiko Sugiura
Yoshiki GODA
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MX2017003780A publication Critical patent/MX2017003780A/es
Publication of MX381440B publication Critical patent/MX381440B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una composición farmacéutica para tratar colitis ulcerativa, que comprende un compuesto representado por una fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde el compuesto o la sal farmacéuticamente aceptable se administra en una cantidad de 600 mg o más por día a un paciente con colitis ulcerativa.(ver Fórmula).
MX2017003780A 2014-09-29 2015-03-27 Composicion farmaceutica para tratar colitis ulcerativa. MX381440B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014198681 2014-09-29
PCT/JP2015/059717 WO2016051828A1 (ja) 2014-09-29 2015-03-27 潰瘍性大腸炎の治療用医薬組成物

Publications (2)

Publication Number Publication Date
MX2017003780A MX2017003780A (es) 2017-06-30
MX381440B true MX381440B (es) 2025-03-12

Family

ID=55629887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003780A MX381440B (es) 2014-09-29 2015-03-27 Composicion farmaceutica para tratar colitis ulcerativa.

Country Status (9)

Country Link
US (1) US10183022B2 (es)
JP (1) JP6580053B2 (es)
KR (1) KR102319078B1 (es)
AU (1) AU2015326196B2 (es)
BR (1) BR112017006272A2 (es)
CA (1) CA2961311C (es)
EA (1) EA034956B1 (es)
MX (1) MX381440B (es)
WO (1) WO2016051828A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3514235B8 (de) * 2018-01-18 2024-02-14 Sterna Biologicals GmbH Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
KR102758046B1 (ko) 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN114668775B (zh) * 2022-02-28 2023-12-19 中国药科大学 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用
US20250206825A1 (en) 2022-03-11 2025-06-26 Osaka University Composition for preventing or treating myocarditis, comprising vla-4 inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325480C (zh) 2000-08-18 2007-07-11 味之素株式会社 苯基丙氨酸衍生物
JP4572832B2 (ja) 2003-02-20 2010-11-04 味の素株式会社 キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
ES2360064T3 (es) 2003-11-14 2011-05-31 Ajinomoto Co., Inc. Dispersión sólida o preparación de dispersión sólida medicinal de un derivado de fenilalanina.
EP1683525B1 (en) 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
EP1688410B1 (en) 2003-11-27 2014-03-05 Ajinomoto Co., Inc. Crystal of phenylalanine derivative and process for producing the same
CA2613249A1 (en) 2005-06-21 2006-12-28 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives, production method thereof and use thereof
ATE549321T1 (de) 2006-11-22 2012-03-15 Ajinomoto Kk Verfahren zur herstellung von phenylalaninderivaten mit chinazolindiongerüsten, und zwischenprodukte für die herstellung
US7987289B2 (en) 2008-06-24 2011-07-26 Microsoft Corporation Participating in cloud as totally stubby edge
CN106963741A (zh) 2010-03-29 2017-07-21 Ea制药株式会社 含有苯基丙氨酸衍生物的医药制剂
ES2549768T3 (es) * 2010-03-29 2015-11-02 Ajinomoto Co., Inc. Cristal de sal hidrocloruro de derivado de fenilalanina

Also Published As

Publication number Publication date
CA2961311A1 (en) 2016-04-07
MX2017003780A (es) 2017-06-30
KR20170057435A (ko) 2017-05-24
AU2015326196B2 (en) 2020-05-14
KR102319078B1 (ko) 2021-10-29
CA2961311C (en) 2022-12-06
US20170196870A1 (en) 2017-07-13
US10183022B2 (en) 2019-01-22
WO2016051828A1 (ja) 2016-04-07
EA201790726A1 (ru) 2017-11-30
AU2015326196A1 (en) 2017-03-23
JPWO2016051828A1 (ja) 2017-07-27
EA034956B1 (ru) 2020-04-10
JP6580053B2 (ja) 2019-09-25
BR112017006272A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12016502355B1 (en) Pharmaceutical composition
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом
IN2014MU01184A (es)
MD4458B1 (ro) Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
EA201892708A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA95834U (uk) Спосіб лікування гострого ішемічного інсульту